Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.14 is 75% above its 5-year average of -0.56, near the high end of its 5-year range (-0.95–-0.02).
25.53% above its 12-month average of -0.19.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.06.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:21:49.405Z. Historical observations retain their original dates. Historical series through 2024-11-08.
EARNINGS PER SHARE (EPS)
-0.14
EARNINGS PER SHARE (EPS) AVG TTM
-0.19
EARNINGS PER SHARE (EPS) AVG 3Y
-0.48
EARNINGS PER SHARE (EPS) AVG 5Y
-0.56
EARNINGS PER SHARE (EPS) AVG 10Y
-0.48
EARNINGS PER SHARE (EPS) AVG 15Y
-0.47
EARNINGS PER SHARE (EPS) AVG 20Y
-0.44
CURRENT VS TTM AVG
+25.53%
CURRENT VS 3Y AVG
+70.92%
CURRENT VS 5Y AVG
+74.97%
CURRENT VS 10Y AVG
+70.71%
CURRENT VS 15Y AVG
+70.11%
CURRENT VS 20Y AVG
+67.91%
Fennec Pharmaceuticals Inc.
Market Cap
$368.91M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$366.39M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$373.40M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
Market Cap
$363.54M
Earnings Per Share (EPS)
2.65
TTM Avg
-5.30
3Y Avg
-10.00
5Y Avg
-10.52
Market Cap
$361.64M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.30
3Y Avg
-1.38
5Y Avg
-1.95
Market Cap
$348.85M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$348.59M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
Market Cap
$345.48M
Earnings Per Share (EPS)
-1.18
TTM Avg
-0.80
3Y Avg
-0.80
5Y Avg
-0.72
Market Cap
$339.15M
Earnings Per Share (EPS)
-1.58
TTM Avg
-1.99
3Y Avg
-1.86
5Y Avg
-1.78
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | $368.91M | -0.14 | -0.19 | -0.48 | -0.56 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -2.41 | -4.66 | -5.40 | -4.56 |
| Canopy Growth Corporation (CGC)vs › | $373.40M | -0.50 | -5.17 | -17.19 | -12.52 |
| Agenus Inc. (AGEN)vs › | $363.54M | 2.65 | -5.30 | -10.00 | -10.52 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -1.30 | -1.38 | -1.95 |
| Embecta Corp. (EMBC)vs › | $348.85M | 1.48 | 1.49 | 2.03 | 3.82 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -3.31 | -3.43 | -2.65 | -2.61 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -1.18 | -0.80 | -0.80 | -0.72 |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -1.58 | -1.99 | -1.86 | -1.78 |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -1.71 | -1.36 | -1.12 | -1.12 |
Trailing EPS (TTM)
$-0.14
Forward EPS (Est.)
$0.28
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.36 |
| 2024-12-31 | -0.02 |
| 2023-12-31 | -0.60 |
| 2022-12-31 | -0.95 |
| 2021-12-31 | -0.67 |
| 2020-12-31 | -0.76 |
| 2019-12-31 | -0.63 |
| 2018-12-31 | -0.52 |
| 2017-12-31 | -0.47 |
| 2016-12-31 | -0.22 |
| 2015-12-31 | -0.06 |
| 2014-12-31 | -0.22 |
| 2013-12-31 | 0.19 |
| 2012-12-31 | -0.63 |
| 2011-12-31 | 0.59 |
| 2010-12-31 | -1.11 |
| 2009-12-31 | -0.98 |
| 2008-12-31 | -4.43 |
| 2007-12-31 | -4.78 |
| 2006-12-31 | -16.72 |
| 2005-12-31 | -13.20 |
| 2004-06-30 | -15.04 |
| 2003-06-30 | -19.85 |
| 2002-06-30 | -19.32 |
| 2001-06-30 | -4.04 |
| 2000-06-30 | -2.98 |
